Stockscreener 앱 받기
8.20
4.24%
0.41
전일 마감가:
$7.79
열려 있는:
$7.78
하루 거래량:
39,633
Relative Volume:
0.49
시가총액:
$188.74M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+15.67%
1개월 성능:
+21.74%
6개월 성능:
+6.01%
1년 성능:
+10.48%
1일 변동 폭
$7.78
$8.3037
1주일 범위
$6.87
$8.49
52주 변동 폭
$5.47
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
명칭
Actuate Therapeutics Inc
전화
847-986-4190
주소
1751 RIVER RUN, FORT WORTH
ACTU을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
8.12 | 181.07M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.60 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.54 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.70 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.41 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-26 | 개시 | B. Riley Securities | Buy |
| 2025-04-22 | 개시 | Craig Hallum | Buy |
| 2025-03-17 | 개시 | H.C. Wainwright | Buy |
Actuate Therapeutics Inc 주식(ACTU)의 최신 뉴스
Using Bollinger Bands to evaluate Actuate Therapeutics Inc.Trade Volume Summary & Long-Term Growth Portfolio Plans - newser.com
Actuate Therapeutics Inc. stock retracement – recovery analysisWeekly Trend Report & Entry Point Strategy Guides - newser.com
Heatmap analysis for Actuate Therapeutics Inc. and competitorsSell Signal & Safe Entry Trade Reports - newser.com
How to forecast Actuate Therapeutics Inc. trends using time series2025 Earnings Surprises & Technical Buy Zone Confirmations - newser.com
Risk vs reward if holding onto Actuate Therapeutics Inc.Dollar Strength & Real-Time Market Trend Scan - newser.com
How hedge fund analytics apply to Actuate Therapeutics Inc. stock2025 Market Sentiment & Free High Accuracy Swing Entry Alerts - newser.com
Will Actuate Therapeutics Inc. stock see insider buyingPortfolio Risk Report & Fast Exit and Entry Trade Guides - newser.com
Can Actuate Therapeutics Inc. stock deliver sustainable ROETrade Exit Summary & Low Risk Profit Maximizing Plans - newser.com
Reversal indicators forming on Actuate Therapeutics Inc. stock2025 Valuation Update & Daily Chart Pattern Signal Reports - newser.com
Myelofibrosis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros - Barchart.com
Actuate Therapeutics (NASDAQ:ACTU) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Applying Elliott Wave Theory to Actuate Therapeutics Inc.2025 Momentum Check & Expert Curated Trade Ideas - newser.com
Price action breakdown for Actuate Therapeutics Inc.Market Volume Report & Growth Focused Investment Plans - newser.com
Is Actuate Therapeutics Inc. trending in predictive chart models2025 Big Picture & Free Daily Entry Point Trade Alerts - newser.com
Evaluating Actuate Therapeutics Inc. with trendline analysisJuly 2025 Patterns & Weekly Top Gainers Trade List - newser.com
How to build a custom watchlist for Actuate Therapeutics Inc.2025 Top Decliners & AI Based Buy and Sell Signals - newser.com
Is Actuate Therapeutics Inc. forming a reversal patternWeekly Earnings Recap & Low Risk Investment Opportunities - newser.com
Craig-Hallum Maintains Actuate Therapeutics(ACTU.US) With Buy Rating - 富途牛牛
H.C. Wainwright Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
B.Riley Financial Initiates Actuate Therapeutics(ACTU.US) With Buy Rating, Announces Target Price $20 - 富途牛牛
Pancreatic Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Bio, Keymed Biosciences, Carisma Therapeu - Barchart.com
Relative strength of Actuate Therapeutics Inc. in sector analysisPortfolio Return Report & AI Enhanced Execution Alerts - newser.com
Published on: 2025-10-02 23:42:39 - newser.com
Ataxia Telangiectasia Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight - openPR.com
Actuate Therapeutics Inc Stock Analysis and ForecastHigh Beta Stocks & Budget Friendly Investment Plans - earlytimes.in
Goldman Sachs Group Inc. Has $151,000 Holdings in Actuate Therapeutics, Inc. $ACTU - Defense World
Myelofibrosis Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
Myelofibrosis Market Outlook 2034Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - openPR.com
Published on: 2025-09-29 03:19:58 - newser.com
What analysts say about Actuate Therapeutics Inc stockShort-Term Trading Alerts & Trade Like a Pro Using AI Edge - Early Times
Actuate Therapeutics Inc (ACTU) 재무 분석
Actuate Therapeutics Inc (ACTU)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Actuate Therapeutics Inc 주식 (ACTU) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | Director |
Jun 27 '25 |
Buy |
7.00 |
71,428 |
499,996 |
196,428 |
| Fletcher Aaron G.L. | Director |
Jun 27 '25 |
Buy |
7.00 |
71,428 |
499,996 |
196,428 |
1.24%
자본화:
|
볼륨(24시간):